{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:12:14Z","timestamp":1760141534145,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013684","name":"Christie Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013684","name":"Christie Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejso.2020.03.210","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T02:56:51Z","timestamp":1585277811000},"page":"583-590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"PA","title":["Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5342-1480","authenticated-orcid":false,"given":"Zainul Abedin","family":"Kapacee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"de Liguori Carino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-0863","authenticated-orcid":false,"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2020.03.210_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","article-title":"Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability","volume":"19","author":"Mcglynn","year":"2015","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.ejso.2020.03.210_bib2","article-title":"International trends in hepatocellular carcinoma incidence, 1978\u20132012","author":"Petrick","year":"2019","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejso.2020.03.210_bib3","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.ejso.2020.03.210_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cncr.30246","article-title":"Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States","volume":"123","author":"Yang","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2020.03.210_bib5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2020.03.210_bib6","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41416-018-0029-6","article-title":"The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015","volume":"118","author":"Brown","year":"2018","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejso.2020.03.210_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejso.2020.03.210_bib8","unstructured":"Liver cancer mortality statistics | Cancer Research UK n.d. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/liver-cancer\/mortality#heading-One (accessed January 19, 2020)."},{"key":"10.1016\/j.ejso.2020.03.210_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"volume":"vol. 69","year":"2018","author":"Galle","key":"10.1016\/j.ejso.2020.03.210_bib10"},{"key":"10.1016\/j.ejso.2020.03.210_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3748\/wjg.v12.i1.48","article-title":"Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival","volume":"12","author":"Tsukioka","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejso.2020.03.210_bib12","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.3748\/wjg.v25.i27.3563","article-title":"Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients?","volume":"25","author":"Ka","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejso.2020.03.210_bib13","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4254\/wjh.v7.i11.1521","article-title":"Management of hepatocellular carcinoma in the elderly","volume":"7","author":"Borzio","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ejso.2020.03.210_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","article-title":"Search: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma","volume":"33","author":"Zhu","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib15","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib16","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"Cheng","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib17","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/annonc\/mdy101","article-title":"Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma","volume":"29","author":"Abou-Alfa","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib18","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.ejso.2020.03.210_bib19","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31","author":"Llovet","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.ejso.2020.03.210_bib21","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(18)30146-3","article-title":"Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study","volume":"19","author":"Rimassa","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib22","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2020.03.210_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2020.03.210_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2020.03.210_bib25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib26","doi-asserted-by":"crossref","first-page":"ix186","DOI":"10.1093\/annonc\/mdz446.002","article-title":"IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo)\u00a0+ bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"30","author":"Cheng","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2020.03.210_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib29","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.ejso.2020.03.210_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","article-title":"Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinomada meta-analysis","volume":"105","author":"Geraldine McNamara","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejso.2020.03.210_bib31","first-page":"268","article-title":"Advances in cancer immunotherapy 2019 - latest trends","volume":"38","author":"Kruger","year":"2019","journal-title":"J\u00a0Exp Clin Canc Res"},{"key":"10.1016\/j.ejso.2020.03.210_bib32","doi-asserted-by":"crossref","unstructured":"Shi F, Shi M, Zeng Z, Qi R-Z, Liu Z-W, Zhang J-Y, et\u00a0al. PD-1 and PD-L1 upregulation promotes CD8 1 T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients n.d. https:\/\/doi.org\/10.1002\/ijc.25397.","DOI":"10.1002\/ijc.25397"},{"key":"10.1016\/j.ejso.2020.03.210_bib33","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Gao","year":"2009","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejso.2020.03.210_bib34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A\u00a0model to predict survival in patients with end-stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.ejso.2020.03.210_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz154.026","article-title":"Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240","volume":"30","author":"Finn","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib36","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib38","doi-asserted-by":"crossref","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib39","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Wang","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2020.03.210_bib40","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/ageing\/afi146","article-title":"What would make a definition of frailty successful?","volume":"34","author":"Rockwood","year":"2005","journal-title":"Age Ageing"},{"key":"10.1016\/j.ejso.2020.03.210_bib41","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"Journals Gerontol Ser A Biol Sci Med Sci"},{"key":"10.1016\/j.ejso.2020.03.210_bib42","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jgo.2018.03.001","article-title":"Geriatric oncology screening tools for CGA-based interventions: results from a phase II study of geriatric assessment and management for older adults with cancer","volume":"9","author":"Yokom","year":"2018","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.ejso.2020.03.210_bib43","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/liv.13917","article-title":"Frailty in advanced liver disease","volume":"38","author":"Laube","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.ejso.2020.03.210_bib44","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.29219","article-title":"Development of a novel frailty index to predict mortality in patients with end-stage liver disease","volume":"66","author":"Lai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejso.2020.03.210_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cld.825","article-title":"Frailty assessment in patients with liver cirrhosis","volume":"14","author":"Van Jacobs","year":"2019","journal-title":"Clin Liver Dis"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798320303693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798320303693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:37:01Z","timestamp":1760060221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798320303693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0748798320303693"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2020.03.210","relation":{},"ISSN":["0748-7983"],"issn-type":[{"type":"print","value":"0748-7983"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2020.03.210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}